Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer.
84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT.
Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p
This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.
Clinical trial identification
Legal entity responsible for the study
Guangdong General Hospital
All authors have declared no conflicts of interest.